vimarsana.com
Home
Live Updates
Avacta : ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data -December 13, 2023 at 02:03 am EST : comparemela.com
Avacta : ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data -December 13, 2023 at 02:03 am EST
The data confirm the pre|CISIONTM platform's ability to transform the safety profile of doxorubicin through tumour targeting
Cohort 7, the final cohort in the three-weekly dose...
Related Keywords
United States ,
Alastair Smith ,
Christina Coughlin ,
Fiona Mclaughlin ,
Investor Meet Company ,
Avacta Group ,
Fibroblast Activation Protein ,
Undifferentiated Pleomorphic Sarcoma ,
Chief Executive Officer ,
William Tap ,
Sarcoma Medical Oncology ,
Memorial Sloan Kettering Cancer Center ,
Chief Executive Officer Alastair Smith ,
Chief Scientific Officer Fiona Mclaughlin ,
Consultant Christina Coughlin ,
Markets ,
comparemela.com © 2020. All Rights Reserved.